高级检索
当前位置: 首页 > 详情页

Tongxinluo ameliorates renal structure and function by regulating miR-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Sch Tradit Chinese Med, Metab Dis Ctr, Beijing 100069, Peoples R China [2]Capital Med Univ, Tongren Hosp, Dept Endocrinol, Beijing 100069, Peoples R China [3]Capital Med Univ, Dept Endocrinol & Metab, Beijing 100069, Peoples R China [4]Capital Med Univ, Dept Pathophysiol, Beijing 100069, Peoples R China
出处:
ISSN:

关键词: tongxinluo (TXL) microRNA epithelial-to-mesenchymal transition (EMT) diabetic nephropathy

摘要:
Diabetic nephropathy (DN) is one of the most important diabetic microangiopathies. The epithelial-to-mesenchymal transition (EMT) plays an important role in DN. The physiological role of microRNA-21 (miR-21) was closely linked to EMT. However, it remained elusive whether tongxinluo (TXL) ameliorated renal structure and function by regulating miR-21-induced EMT in DN. This study aimed to determine the effect of TXL on miR-21-induced renal tubular EMT and to explore the relationship between miR-21 and TGF-beta 1/smads signals. Real-time RT-PCR, cell transfection, in situ hybridization (ISH), and laser confocal microscopy were used, respectively. Here, we revealed that TXL dose dependently lowered miR-21 expression in tissue, serum, and cells. Overexpression of miR-21 can enhance alpha-smooth muscle actin (SMA) expression and decrease E-cadherin expression by upregulating smad3/p-smad3 expression and downregulating smad7 expression. Interestingly, TXL also increased E-cadherin expression and decreased alpha-SMA expression by regulating miR-21 expression. More importantly, TXL decreased collagen IV, fibronectin, glomerular basement membrane, glomerular area, and the albumin/creatinine ratio, whereas it increased the creatinine clearance ratio. The results demonstrated that TXL ameliorated renal structure and function by regulating miR-21-induced EMT, which was one of the mechanisms to protect against DN, and that miR-21 may be one of the therapeutic targets for TXL in DN.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 2 区 医学
小类 | 2 区 生理学 2 区 泌尿学与肾脏学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 生理学 2 区 泌尿学与肾脏学
JCR分区:
出版当年[2012]版:
Q1 UROLOGY & NEPHROLOGY Q1 PHYSIOLOGY
最新[2024]版:
Q1 PHYSIOLOGY Q1 UROLOGY & NEPHROLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者机构: [1]Capital Med Univ, Sch Tradit Chinese Med, Metab Dis Ctr, Beijing 100069, Peoples R China [2]Capital Med Univ, Tongren Hosp, Dept Endocrinol, Beijing 100069, Peoples R China [3]Capital Med Univ, Dept Endocrinol & Metab, Beijing 100069, Peoples R China
通讯作者:
通讯机构: [1]Capital Med Univ, Sch Tradit Chinese Med, Metab Dis Ctr, Beijing 100069, Peoples R China [*1]Capital Med Univ, Sch Tradit Chinese Med, Metab Dis Ctr, 10 Youanmenwai Xitoutiao, Beijing 100069, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:28517 今日访问量:0 总访问量:1589 更新日期:2025-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)